ZACCARDELLI DAVID 4
Research Summary
AI-generated summary
Vor Biopharma (VOR) Director David Zaccardelli Receives 42,658-Share Award
What Happened David Zaccardelli, a director of Vor Biopharma, was granted 42,658 derivative shares on July 7, 2026. The Form 4 reports a $0.00 acquisition price (award/derivative), indicating a compensation grant rather than an open‑market purchase or sale. The Form 4 was filed July 9, 2026 (appears to be timely).
Key Details
- Transaction date: 2026-07-07; Form 4 filed: 2026-07-09
- Transaction type: Award/derivative (Code A) — 42,658 shares granted at $0.00
- Vesting: Shares vest in 36 equal monthly installments beginning August 7, 2026, contingent on continued service (footnote F1)
- Shares owned after transaction: not disclosed in this filing
- This is a compensation/retention grant (derivative award), not a sale or purchase
Context Derivative awards like this are commonly used for director compensation and retention (often structured as restricted stock units or similar). Because the grant vests over three years and no sale or exercise occurred, it does not represent an immediate market buy or sell signal — it reflects standard equity compensation tied to continued service.